{"entity":{"id":"nct07535632","kind":"trial","name":"SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer","aka":["BEST"],"tldr":"A phase 2 trial of sintilimab and bevacizumab (glioblastoma use) in colorectal cancer, run by Shanghai Zhongshan Hospital, not yet recruiting.","summary":"SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer is a phase 2, randomised interventional study registered as NCT07535632 by Shanghai Zhongshan Hospital, with a registry enrolment figure of 58 participants, started 2026-06-01 and due to reach its primary completion in 2028-06-01. Interventions recorded: SBRT; Sintilimab; Bevacizumab; Trifluridine and Tipiracil Tablets; Standard of Care (Investigator Selected). Conditions listed: Colorectal Neoplasms. Primary outcome: Progression-Free Survival (PFS). Colorectal eligibility wording from the registry: \"Histologically or cytologically confirmed colorectal cancer with unresectable metastatic or recurrent lesions\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07535632","url":"https://clinicaltrials.gov/study/NCT07535632"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","sbrt"],"targets":[],"drugs":["sintilimab","bevacizumab-glioma"],"companies":["innovent"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07535632","phase":"2","setting":"A Phase II Clinical Study on the Efficacy of Stereotactic Body Radiation Therapy Sequential Combined With Bevacizumab and Trifluridine/Tipiracil in the Treatment of Recurrent Metastatic Colorectal Cancer(BEST)","sponsor":"Shanghai Zhongshan Hospital","enrolled":58,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07535632/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"}],"company":[{"id":"innovent","kind":"company","name":"Innovent Biologics","route":"/companies/innovent/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}